2016
DOI: 10.1016/j.bmcl.2016.01.025
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of diamide compounds as diacylglycerol acyltransferase 1 (DGAT1) inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 16 publications
0
2
0
Order By: Relevance
“…Replacement of Phe in enkephalin analogs provided 2-fold enhancement of morphine-like activity. 137 Dipeptide antagonists of substance P with specificity for the NK-1 receptor were prepared with a number of unnatural aromatic amino acids, such as 3-(6-methyl-2-naphthyl)-Ala, 3-(6-chloro-2-naphthyl)-Ala, 3-(5,6,7,8-tetrahydro-2-naphthyl)-Ala (188), and 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-Ala (189), 149 or with a number of conformationally restricted 193), (E)-dehydro-Phe (194), and (Z)-dehydro-Phe (195)). 150 Tic (196) is commonly used as a conformationally restricted replacement for Phe, reducing the movement of the aromatic ring as well as the peptide backbone.…”
Section: Journal Of Medicinal Chemistrymentioning
confidence: 99%
See 1 more Smart Citation
“…Replacement of Phe in enkephalin analogs provided 2-fold enhancement of morphine-like activity. 137 Dipeptide antagonists of substance P with specificity for the NK-1 receptor were prepared with a number of unnatural aromatic amino acids, such as 3-(6-methyl-2-naphthyl)-Ala, 3-(6-chloro-2-naphthyl)-Ala, 3-(5,6,7,8-tetrahydro-2-naphthyl)-Ala (188), and 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-Ala (189), 149 or with a number of conformationally restricted 193), (E)-dehydro-Phe (194), and (Z)-dehydro-Phe (195)). 150 Tic (196) is commonly used as a conformationally restricted replacement for Phe, reducing the movement of the aromatic ring as well as the peptide backbone.…”
Section: Journal Of Medicinal Chemistrymentioning
confidence: 99%
“…N -Methylation is one common approach that introduces conformational constraints which can significantly affect ligand potency and receptor subtype selectivity . A peptide to peptidomimetic transformation is nicely illustrated in a recent paper from Novartis (Scheme ), in which a tripeptide-like diacylglycerol acyltransferases (DGAT1) inhibitor 241 (DGAT1 IC 50 = 0.007 μM, but not bioavailable or efficacious when dosed orally to rats) was first C -terminal modified ( 242 ), then N -terminal modified ( 243 ), and then further derivatized to produce 245 , with IC 50 = 0.062 μM, improved solubility, gut permeability and metabolic stability, high oral bioavailability (76%), and oral efficacy . Attempts to remove the central amino acid residue produced an inactive compound 244 .…”
Section: Unusual Amino Acids In Drugsmentioning
confidence: 99%